Effective January 15, 2024, Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has appointed Zhao Ping as the chairman of its China operations. This strategic appointment comes as the company looks to strengthen its presence and leadership in the Chinese market.
Zhao Ping brings a wealth of experience to her new role. She holds a Bachelor’s degree in Medicine from the School of Medicine at Tongji University in Shanghai and an MBA from the University of Leicester in the UK. Her extensive career includes serving as the CEO of Bennubio and holding China general manager positions at renowned pharmaceutical companies such as Genzyme, Allergan, BMS, and CStone Pharma. In the early stages of her career, Zhao Ping contributed her expertise to Eli Lilly and BMS.- Flcube.com
